Daiichi To Use Ranbaxy Buy To Enter Africa, East Europe
This article was originally published in PharmAsia News
Daiichi Sankyo plans to expand into Eastern European and African markets by taking advantage of the network of Ranbaxy Laboratories, which Daiichi is acquiring. The Japanese company plans to own more than 50.1 percent of Ranbaxy by December, enabling it to apply for foreign drug-marketing authorizations. Many of its intended sales are generics for drugs about to lose patent protection, but it has not decided which of those to emphasize. The firm expects big sales from antibacterial agents for contagious diseases. Ranbaxy, based in Gurgaon, India, has a presence in 49 markets, Daiichi 20. (Click here for more - a subscription may be required
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The International Medical Device Regulators Forum, perhaps most notorious for its efforts to standardize audit processes between nations with its Medical Device Single Audit Program, is also focusing on harmonizing device reviews and adverse event codes.
Dr Reddy’s Laboratories has become the third Revlimid ANDA sponsor to settle patent litigation action with Bristol Myers Squibb’s Celgene. However, the Indian company will join Alvogen in not being able to launch before first settler Natco, which has partnered with Teva’s Watson.